Trial Profile
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Bladder cancer
- Focus Biomarker; Pharmacodynamics
- 15 Jan 2020 Status changed from recruiting to discontinued.
- 09 Jul 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
- 17 Sep 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2018 to 1 Oct 2018.